ArticleBBA advances2024
Emerging technologies for single-cell glycomics.
Article in BBA advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- Single-Cell Glycomics of the Pancreatic Tumor Microenvironment: Technologies, Glyco-Immune Checkpoints, and Tumor-Immune Communication.Advanced biology · 2026Review
- Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation.Signal transduction and targeted therapy · 2026Review
- Glycosylation converts CD24 from a developmental marker into a glyco-immune checkpoint in B-cell acute lymphoblastic leukemia.Frontiers in immunology · 2026Review
- Hematologic Glyco-Signatures: Emerging Blood-Based Sugar Codes Linked to Hyper-Aggressive Breast Cancer.Breast cancer (Dove Medical Press) · 2026Review
- Decoding sialidase: physiological roles, pathological pathways, and clinical opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Galectin-3 and the Glyco-Inflammatory Axis: A Missing Link to Residual Cardiovascular Risk in Coronary Artery Disease.Biomedicines · 2025Review
- Review
- Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery.Biomedicines · 2025Review
- Introduction to a special issue, "Expanded glycomics: A bridge over future glycomics".BBA advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycans are present on virtually all cellular surfaces and are important regulators of multicellular communications. Advances in single-cell omics technologies have revolutionized life science research by elucidating cellular heterogeneity through integrated multimodal analyses, providing a comprehensive view of cellular functions. However, dissecting the heterogeneity of glycans at the single-cell level has been challenging due to their structural complexity and unamplifiable nature. Recently, we developed a novel technology called single-cell glycan and RNA sequencing (scGR-seq), which converts glycan information into genetic information using DNA-barcoded lectins, amplifies it by PCR, and simultaneously measures the glycome and transcriptome in thousands of single cells on a next-generation sequencer. In this mini-review, we review the recent advances in single-cell glycomics, focusing on our scGR-seq technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.